Corpus overview


MeSH Disease

Human Phenotype

Diarrhea (35)

Fever (25)

Cough (25)

Fatigue (13)

Pneumonia (10)


    displaying 1 - 10 records in total 35
    records per page

    Clinical characteristics of pediatric cases of SARS-CoV-2 infection MESHD in Hunan, China: A retrospective, multi-center case series

    Authors: Lei Wu; Xiao-Fo Zhang; Jia Li; Song-Qing Wei; Yong Yang; Xiu-Ying Yi; Xin-Ping Jiang; Hai-Ying Han; Zhe-Feng Zhong; Xiao-Ying Cao; Feng-Jun L; Ge Zhou; Xiao-Hui Gong; Wen-Ting Zha; He-Bin Xie; Tuan-Mei Wang; Man-Zhi Wang

    doi:10.21203/ Date: 2020-09-15 Source: ResearchSquare

    Objective To investigate the epidemiological characteristics, clinical features, treatment and short-term prognosis of SARS-CoV-2 infection MESHD in children TRANS.Methods A retrospective analysis was conducted in children TRANS with SARS-CoV-2 admitted to twelve hospitals in eight cities in Hunan province, China, from January 26, 2020 to June 30, 2020.Results A total of 48 children were enrolled in this study. 11 cases (23%) were asymptomatic TRANS, 15 cases (31%) were mild, 20 cases (42%) were moderate, and 2 cases (4%) were severe. No children TRANS were critical requiring intensive care. The most common symptom was fever HP fever MESHD (42%), cough HP (40%), fatigue MESHD (17%) and diarrhea HP diarrhea MESHD (10%). The total peripheral blood SERO leukocytes count decreased in two case (4%), Lymphocytopenia MESHD was present in 5 cases (10%). There were abnormal chest CT changes in 22 children (46%), including 15 (68%) with patchy ground glass opacity. In addition to supportive treatment, 41 children TRANS (85%) received antiviral therapy, 11 patients and (23%) were treated with antibiotics, 2 children TRANS (4%) were treated with methylprednisolone and IVIG. There was no death occurred.Conclusions Most children TRANS with SARS CoV-2 infection MESHD in Hunan province were asymptomatic TRANS, mild or moderate. Severe cases are rare. Close family contact was the main route of infection MESHD. The younger the age TRANS, the less obvious symptoms for children TRANS might be. Epidemiological history, nucleic acid test and chest imaging were important tools for the diagnosis in children TRANS.

    New onset of Myasthenia Gravis MESHD in a patient with COVID-19: A novel case report and literature review

    Authors: Shitiz Sriwastava; Medha Tandon; Saurabh Kataria; Maha Daimee; Shumaila Sultan

    doi:10.21203/ Date: 2020-09-14 Source: ResearchSquare

    The novel coronavirus outbreak of SARS-CoV-2 first began in Wuhan, China in December, 2019. The most striking manifestation is atypical pneumonia HP pneumonia MESHD and respiratory complications MESHD, however various neurological manifestations are now well recognized. Currently, there have been a very few case reports in regards to COVID-19 in patients with known history of myasthenia gravis MESHD. Myasthenia gravis MESHD ( MG MESHD) causes muscle weakness HP muscle weakness MESHD, especially respiratory muscles in high-risk COVID-19 patients that can lead to severe respiratory compromise. There are few reported cases of severe myasthenia crisis MESHD following COVID-19, likely due to the involvement of the respiratory apparatus and from use of immunosuppressive medication. We report a first case MG MESHD developing secondary to COVID-19 infection MESHD in a 65-year-old woman. Two weeks prior to hospitalization, the patient suffered from cough HP, fever HP fever MESHD, diarrhea HP diarrhea MESHD and was found to be positive for COVID-19 via nasopharyngeal RT-PCR swab test. The electrodiagnostic test showed decremental response over more than 10% on repetitive nerve stimulation test of orbicularis oculi. She tested positive for antibodies SERO against Acetylcholine receptor (AchR).COVID-19 is known to cause release of inflammatory cytokines leading to immune-mediated damage. MG MESHD is an immune-mediated disorder caused due to molecular mimicry and autoantibodies against the neuromuscular junction. 

    Effects of COVID-19 on the Gut and the Liver - A Case Series of 711 Patients in New York City

    Authors: Sher Nazir Baig, MD; Fuad Abaleka, MD; Stephanie Herrera, MD; Mina Daniel, MD; Bisrat Nigusse, MD; Thu M Vu, MD; Tigist Gemechu, MD; George Abdelsayed, MD, FACG

    doi:10.21203/ Date: 2020-08-06 Source: ResearchSquare

    Background As the COVID-19 epidemic is wreaking havoc with a staggering number of infections MESHD and fatalities worldwide, digestive symptoms are increasingly coming to the limelight. However, the data on the extent of gut and liver involvement has been variable and somewhat conflicting.Methods We identified 711 adults TRANS who had tested positive for COVID-19 at Richmond University Medical Center in New York between March 13 and May 13, 2020. We analyzed their clinical and laboratory data from electronic medical records.Results The average age TRANS of the patients was 60.5 years; 55% were men. 27.1% reported a gastrointestinal ( GI MESHD) symptom and 56.9% had at least one abnormal liver enzyme. The most common was diarrhea HP diarrhea MESHD with a frequency of 17.3% followed by nausea HP nausea MESHD 16.2% and vomiting HP vomiting MESHD/ anorexia HP anorexia MESHD 13.7%. Abdominal pain HP Abdominal pain MESHD 5.6%, dysgeusia MESHD 3.2%, and GI bleeding MESHD 2.2% was the least common. Symptoms were mostly mild and lasted 3-5 days. The liver function was deranged in more than half of the patients. AST alone was elevated in 16.6%, both AST/ALT 15.7%, alkaline phosphatase 23%, and bilirubin 10%. Potential confounders were rare but included preexisting liver disease MESHD and hepatotoxic MESHD medications. Prothrombin time (PT) was mildly elevated in 13.4%. The lipase was elevated in 2.4% without upper abdominal pain HP abdominal pain MESHD. In 75%-90% of cases, liver test abnormalities MESHD were mild (1.5-3 x normal). Overall, 86.6% of patients were admitted primarily with respiratory failure HP respiratory failure MESHD and 28.5% died of their illness.Conclusions 27% of COVID-19 patients experienced a digestive disturbance and >55% showed a predominantly mild degree of liver dysfunction MESHD and cholestasis HP cholestasis MESHD.

    Clinical Characteristics of Pediatric Inflammatory Multisystem Syndrome MESHD Associated With COVID-19

    Authors: Leila Shahbaznejad; Mohammad Reza Navaifar; Ali Abbaskhanian; Fatemeh Hosseinzadeh; Mohammad Sadegh Rezai

    doi:10.21203/ Date: 2020-07-30 Source: ResearchSquare

    Background: Although symptoms and signs of COVID-19 (Coronavirus disease 2019) in children TRANS are milder than adults TRANS, there are reports of more severe cases which was defined as pediatric inflammatory multisystem syndrome MESHD ( PIMS MESHD). The purpose of this report is to describe possible association between COVID-19 and PIMS in children TRANS.  Methods: From 28 March to 24 June 2020, 10 febrile children TRANS were admitted with COVID-19 infection MESHD showing characteristics of PIMS in a tertiary hospital in the north of Iran. Demographic and clinical characteristics, laboratory and imaging findings and therapeutic modalities were recorded and analysed. Results: The mean age TRANS of patients was 5.37±3.9 years (13 months to 12 years). Six of them were boy. Kawasaki disease MESHD, myocarditis HP myocarditis MESHD, toxic shock syndrome MESHD shock HP syndrome, appendicitis MESHD, sepsis HP sepsis MESHD, urosepsis, prolonged febrile seizure HP seizure MESHD, acute hemorrhagic edema MESHD edema HP of infancy, and COVID-19-related pneumonia HP pneumonia MESHD were their first impression. All of them had increased C-reactive protein level and most of them had an elevated erythrocyte sedimentation rate HP, lymphopenia HP lymphopenia MESHD, anemia HP, and hypoalbuminemia HP hypoalbuminemia MESHD. Some of them had thrombocytopenia HP thrombocytopenia MESHD. Six of them were serologically or polymerase chain reaction positive for COVID-19, and 4 of them were diagnosed as COVID-19 just by chest computed tomography scan. Most of the patients improved without a residual sequel, except one who died with multiorgan failure MESHD and another case discharged with a giant coronary aneurysm MESHD.Conclusion: Children TRANS with COVID-19 may present symptoms similar to Kawasaki disease MESHD and inflammatory syndromes. PIMS should be considered in children TRANS with fever HP fever MESHD and rash MESHD, seizure HP seizure MESHD, cough HP, tachypnea HP tachypnea MESHD, and gastrointestinal symptoms such as vomiting HP vomiting MESHD, diarrhea HP diarrhea MESHD, and abdominal pain HP abdominal pain MESHD.

    Rapid host response to an infection with Coronavirus. Study of transcriptional responses with Porcine Epidemic Diarrhea HP Diarrhea MESHD Virus

    Authors: Wei Hou; Fei Liu; Wim H.M. van der Poel; Marcel M Hulst

    doi:10.1101/2020.07.28.224576 Date: 2020-07-28 Source: bioRxiv

    The transcriptional response in Vero cells (ATCC(R) CCL-81) infected with the coronavirus Porcine Epidemic Diarrhea Virus MESHD Diarrhea HP Virus (PEDV) was measured by RNAseq analysis 4 and 6 hours after infection MESHD. Differential expressed genes (DEGs) in PEDV infected cells were compared to DEGs responding in Vero cells infected with Mammalian Orthoreovirus (MRV). Functional analysis of MRV and PEDV DEGs showed that MRV increased the expression level of several cytokines and chemokines (e.g. IL6, CXCL10, IL1A, CXCL8 [alias IL8]) and antiviral genes (e.g. IFI44, IFIT1, MX1, OASL), whereas for PEDV no enhanced expression was observed for these "hallmark" antiviral and immune effector genes. Pathway and Gene Ontology "enrichment analysis" revealed that PEDV infection MESHD did not stimulate expression of genes able to activate an acquired immune response, whereas MRV did so within 6h. Instead, PEDV down-regulated the expression of a set of zinc finger proteins with putative antiviral activity and enhanced the expression of the transmembrane serine protease gene TMPRSS13 (alias MSPL) to support its own infection by virus-cell membrane fusion (Shi et al, 2017, Viruses, 9(5):114). PEDV also down-regulated expression of Ectodysplasin A, a cytokine of the TNF-family able to activate the canonical NFKB-pathway responsible for transcription of inflammatory genes like IL1B, TNF, CXCL8 and PTGS2. The only 2 cytokine genes found up-regulated by PEDV were Cardiotrophin-1, an IL6-type cytokine with pleiotropic functions on different tissues and types of cells, and Endothelin 2, a neuroactive peptide with vasoconstrictive properties. Furthermore, by comprehensive datamining in biological and chemical databases and consulting related literature we identified sets of PEDV-response genes with potential to influence i) the metabolism of biogenic amines (e.g. histamine), ii) the formation of cilia and "synaptic clefts" between cells, iii) epithelial mucus production, iv) platelets activation, and v) physiological processes in the body regulated by androgenic hormones (like blood SERO pressure, salt/water balance and energy homeostasis). The information in this study describing a "very early" response of epithelial cells to an infection MESHD with a coronavirus may provide pharmacologists, immunological and medical specialists additional insights in the underlying mechanisms of coronavirus associated severe clinical symptoms including those induced by SARS-CoV-2. This may help them to fine-tune therapeutic treatments and apply specific approved drugs to treat COVID-19 patients.

    Fecal Shedding of SARS-CoV-2 and Its Potential Role in Person-To-Person Transmission TRANS and the Environment-Based Spread of COVID-19

    Authors: Davey Jones; Marcos Quintela Baluja; David Graham; Alexander Corbishley; James McDonald; Shelagh Malham; Luke Hillary; Thomas Connor; William Gaze; Ines Moura; Mark Wilcox; Kata Farkas

    id:10.20944/preprints202007.0471.v1 Date: 2020-07-20 Source:

    The recent detection of SARS-CoV-2 RNA in feces has led to speculation that it can be transmitted via the fecal-oral/ocular route. This review aims to critically evaluate the incidence of gastrointestinal (GI) symptoms MESHD, the quantity and infectivity of SARS-CoV-2 in feces and urine, and whether these pose an infection risk TRANS infection risk TRANS in sanitary settings, sewage networks, wastewater treatment plants, and the wider environment (e.g. rivers, lakes and marine waters). Overall, severe GI dysfunction MESHD is only evident in a small number of COVID-19 cases, with 11 ± 2% exhibiting diarrhea HP diarrhea MESHD and 12 ± 3% exhibiting vomiting and nausea HP vomiting and nausea MESHD nausea MESHD. In addition to these cases, SARS-CoV-2 RNA can be detected in feces from some asymptomatic TRANS, mildly- and pre-symptomatic individuals. Fecal shedding of the virus peaks in the symptomatic period and can persist for several weeks, but with declining abundances in the post-symptomatic phase. SARS-CoV-2 RNA is occasionally detected in urine, but reports in fecal samples are more frequent. The abundance of the virus genetic material in both urine (ca. 102-105 gc/ml) and feces (ca. 102-107 gc/ml) is much lower than in nasopharyngeal fluids (ca. 105-1011 gc/ml). There is strong evidence of multiplication of SARS-CoV-2 in the GI MESHD tract and infectious virus has occasionally been recovered from both urine and stool samples. The level and infectious capability of SARS-CoV-2 in vomit HP remain unknown. In comparison to enteric viruses transmitted via the fecal-oral route (e.g. norovirus, adenovirus), the likelihood of SARS-CoV-2 being transmitted via feces or urine appears lower due to the lower relative amounts of virus present in feces/urine. The biggest risk of transmission TRANS will occur in clinical and care home settings where secondary handling of people and urine/fecal matter occurs. In addition, while SARS-CoV-2 RNA genetic material can be detected by in wastewater, this signal is greatly reduced by conventional treatment. Our analysis also suggests the likelihood of infection MESHD due to contact with sewage-contaminated water (e.g. swimming, surfing, angling) or food (e.g. salads, shellfish) is extremely low or negligible based on very low predicted abundances and limited environmental survival of SARS-CoV-2. These conclusions are corroborated by the fact that over eight million global cases of COVID-19 have occurred, but exposure to feces or wastewater has never been implicated as a transmission TRANS vector.

    A severe coronavirus disease MESHD 2019 patient with high-risk predisposing factors died from massive gastrointestinal bleeding MESHD: a case report

    Authors: Taojiang Chen; Qin Yang; Hongyu Duan

    doi:10.21203/ Date: 2020-07-17 Source: ResearchSquare

    Background: SARS-CoV-2 is highly infectious and has been a significant public health threat. Despite typical manifestations of illness are dominated by respiratory symptom, some patients have concurrent gastrointestinal manifestations, including   nausea MESHD, diarrhea HP diarrhea MESHD, and vomiting HP vomiting MESHD. Massive gastrointestinal bleeding MESHD, however, has rarely been reported. Case presentation: We herein describe a case of severe SARS-CoV-2 infected MESHD patient with several risk factors for poor prognosis, including male TRANS, hypertension HP hypertension MESHD, old age TRANS, mixed bacterial infection MESHD and multilobular infiltration on radiological imaging. After improvement of respiratory status, the onset of gastrointestinal bleeding MESHD occurred, probably resulting from direct viral invasion as evidenced by the positive findings for SARS-CoV-2 in the repeat stool specimens. Although aggressive resuscitation was administered, hematochezia HP hematochezia MESHD was uncontrolled. The patient rapidly deteriorated, suffered cardiac arrest HP cardiac arrest MESHD, and expired. Conclusions: Digestive symptoms could be severe in SARS-CoV-2 infected MESHD patients, especially for the high-risk individuals with predisposing conditions. A more thorough protocol for preventing cross-infection MESHD through faecal-oral transmission TRANS should be implemented in the process of patient care and infection MESHD control.

    Acute acalculous cholecystitis MESHD cholecystitis HP on a COVID-19 patient: a case report

    Authors: Edoardo Mattone; Maria Sofia; Elena Schembari; Valentina Palumbo; Rosario Bonaccorso; Valentina Randazzo; Gaetano La Greca; Carmelo Iacobello; Domenico Russello; Saverio Latteri

    doi:10.21203/ Date: 2020-07-13 Source: ResearchSquare

    Background coronavirus disease-19 (COVID-19) has spread to several countries around the world and has become an unprecedented pandemic. We report an extremely rare case of acute acalculous cholecystitis MESHD cholecystitis HP on a COVID-19 patient. In our knowledge, this is the first report of laparoscopic cholecystectomy performed on a COVID-19 patient.Case presentation: a COVID-19 patient was diagnosed with acute acalculous cholecystitis MESHD cholecystitis HP and a multidisciplinary team decided to perform a percutaneous transhepatic biliary drainage (PTBD) as the first treatment. SARS-CoV-2 RNA was not found in the bile fluid. Because of deterioration of the patient’s clinical conditions, laparoscopic cholecystectomy had to be performed and since the gallbladder was gangrenous MESHD, the severe inflammation MESHD made surgery difficult to perform.Conclusions acalculous cholecystitis MESHD cholecystitis HP was related with mechanical ventilation and prolonged total parenteral nutrition, in this case the gangrenous MESHD histopathology pattern and the gallbladder wall ischemia MESHD was probably caused by vascular insufficiency MESHD secondary to severe acute respiratory distress syndrome MESHD respiratory distress HP syndrome of COVID-19 pneumonia MESHD pneumonia HP. The percutaneous transhepatic gallbladder drainage (PTBD) was performed according to Tokyo Guidelines because of high surgical risk. Laparoscopic cholecystectomy was next performed due to no clinical improvement. The absence of viral RNA in the bile highlights that SARS-CoV-2 is not eliminated with the bile while it probably infects MESHD small intestinal enterocytes which is responsible of gastrointestinal symptoms such as anorexia HP anorexia MESHD, nausea, vomiting HP nausea, vomiting MESHD vomiting MESHD, and diarrhea HP diarrhea MESHD. Although the lack of evidence and guidelines about the management of patient with acute cholecystitis MESHD cholecystitis HP during COVID-19 pandemic, laparoscopic cholecystectomy, at most preceded by PTGBD on high surgical risk patients, remains the gold standard for the treatment of acute cholecystitis MESHD cholecystitis HP on COVID-19 patients.

    Prolonged nucleic acid conversion and false-negative RT-PCR results in Indonesian patients with COVID-19: A case series

    Authors: Ika Trisnawati; Riat Al Khair; Aditya Rifqi Fauzi; Gunadi

    doi:10.21203/ Date: 2020-07-02 Source: ResearchSquare

    Background: Prolonged nucleic acid conversion and false-negative results of real-time reverse transcription polymerase chain reaction (RT-PCR) might occur in some patients with COVID-19 rather than recurrence of infection MESHD. Here, we reported four cases of COVID-19 with prolonged nucleic acid conversion and false-negative results of RT-PCR in our institution.Case presentation: Case 1: A 36-year-old- male TRANS patient complained of coughing HP up phlegm one week before admission. His chest X-rays showed mild pneumonia HP pneumonia MESHD in the right lung. His swab test was confirmed positive for SARS-Cov-2. Besides the last two consecutive negative results, he also had negative results of RT-PCR twice (the 6th and 8th tests) from a total of 11 swab tests. Case 2: A 54-year-old- male TRANS patient complained of shortness of breath MESHD that worsened with activity. He had a comorbidity of diabetes MESHD. His chest X-rays showed inhomogeneous opacity on bilateral paracardial and lateral aspects. His swab test was confirmed positive for SARS-Cov-2. Besides the last two consecutive negative results, he also had negative results of RT-PCR once (the 5th test) from a total of 8 swab tests. Case 3: A 47-year-old man presented with complaints of fever HP fever MESHD, cough HP cough MESHD, sore throat, and diarrhea HP diarrhea MESHD. He had comorbidities of asthma HP asthma MESHD and heart rhythm disorders MESHD. His chest X-rays showed bilateral pneumonia HP pneumonia MESHD. His swab test was confirmed positive for SARS-Cov-2. Besides the last two consecutive negative results, he also showed negative results of RT-PCR twice (the 4th and 6th tests) from a total of 11 swab tests. Case 4: A 56-year-old- female TRANS complained of lethargy HP lethargy MESHD and diarrhea HP diarrhea MESHD. She has a history of hyperthyroidism HP hyperthyroidism MESHD. His chest X-rays showed bilateral pneumonia HP pneumonia MESHD. She was confirmed positive for SARS-Cov-2. Besides the last two consecutive negative results, she also had negative results of RT-PCR twice (the 2nd and 10th tests) from a total of 14 swab tests.Conclusions: Our cases further confirmed TRANS the occurrence of prolonged nucleic acid conversion and the possibility of false negative results of RT-PCR in patients with COVID-19 instead of recurrence of infection MESHD. These findings might have an implication on the management of patients with COVID-19 who have already clinically and radiologically recovered, particularly related to subsequent spreading of the infection MESHD in the community.

    Compassionate Use of Opaganib For Patients with Severe COVID-19

    Authors: Ramzi Kurd; Eli Ben-Chetrit; Hani Karameh; Maskit Bar-Meir

    doi:10.1101/2020.06.20.20099010 Date: 2020-06-23 Source: medRxiv

    Background. Opaganib is a selective sphingosine-kinase (SK)-2 inhibitor with anti-inflammatory and anti-viral properties. Methods. We provided opaganib on a compassionate-use basis to patients with severe COVID-19. Patients who required oxygen support via high-flow nasal cannula (HFNC) were offered the treatment. For comparison, we used a control group with same-sex, same-severity patients. Results. Seven patients received at least one dose of opaganib since April 2, 2020. One patient, who received both hydroxychloroquine and azithromycin, developed diarrhea HP diarrhea MESHD and all his medications were stopped. This was the only adverse effect possibly related to opaganib. A second patient was weaned of oxygen and discharged after receiving two doses of opaganib. Therefore, five patients were included in this analysis. Baseline characteristics were not significantly different between cases and controls. Patients treated with opaganib had significantly faster increase in lymphocyte count. All other clinical outcomes had a non-statistically significant trend in favor of the treatment group: median time to weaning from HFNC was 10 and 15 days in cases vs. controls (HR= 0.3, 95% CI: 0.07-1.7, p=0.2) ,time to ambient air was 13 vs.14.5 days (HR=0.4, 95% CI: 0.15-1.5), none of the cases required mechanical ventilation compared with 33% of controls. Conclusion. In this small cohort of severe COVID-19 patients, opaganib was safe and well tolerated with improvement in both clinical and laboratory parameters in all treated patients. The efficacy of opaganib for COVID-19 infection MESHD should be further tested in randomized placebo-controlled trials.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.